Coformer AI
Coformer AI accelerates drug development by using AI-driven coformer identification to solve poor solubility and bioavailability challenges. The platform pairs APIs with coformers using proprietary molecular mechanism models, then validates solubility gains through robotics-enabled in vitro and in vivo testing. This end-to-end workflow helps pharmaceutical partners reach small-scale human trials within 12 months and a clear path to FDA approval in three years.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Healthcare Technology
- Robotics
Funding
Founders
Founder details are not available yet.
Product
Problem
Nearly 40% of commercialized drugs suffer from poor solubility, leading to low bioavailability and detrimental side effects for patients. Poor solubility also plays a major role in late-stage drug development failures, contributing to over $20 billion in annual waste across the industry.
Solution
Coformer AI accelerates the drug development process end-to-end by using AI to identify and match coformers that make formulations safer and more effective. The platform validates solubility gains in vitro and in vivo through robotics, with partners advancing the best candidates into small-scale human trials. Continuous feedback loops refine formulations to maximize bioavailability, safety, and dosage efficiency. This approach helps companies get proof of viability within a year and a clear path to FDA approval in three years, reducing cost, risk, and time to impact.
Target Audience
Primary customers are pharmaceutical and biotech companies, including product lifecycle managers, R&D teams, and development leaders who need to solve solubility bottlenecks and extend the value of existing or pipeline drugs.
Features
- AI-driven coformer identification and matching using proprietary molecular mechanism models to overcome solubility and bioavailability barriers
- Robotics-enabled in vitro and in vivo validation of solubility gains
- Continuous feedback loops that optimize formulations for maximum bioavailability, safety, and dosage efficiency
- End-to-end workflow from formulation to small-scale human trials within 12 months
- Clear pathway to FDA approval in three years, reducing development timelines and costs
- High-throughput screening approach that delivers safer formulations up to 10x faster than traditional methods
- Two engagement paths: targeted coformer solutions for specific bottlenecks or full finished formulations licensed for clinical advancement